BMS-986490

BMS-986490 is an investigational antineoplastic drug developed by Bristol Myers Squibb. It is a new molecular entity designed to target CEACAM5, a cell surface protein highly expressed in several solid tumors. The drug is being evaluated as both monotherapy and in combination with bevacizumab for the treatment of advanced, unresectable, or metastatic solid tumors—including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and gastric cancer—that have progressed after standard therapies. Its mechanism of action involves targeting CEACAM5-expressing tumor cells, although the precise modality (e.g., monoclonal antibody or other biologic) has not been explicitly disclosed in public sources[3][2][7]. Clinical trials are ongoing to assess its safety and efficacy.